Ligand Reports Fourth Quarter and Full Year 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- Wall Street ends down as oil prices, Treasury yields rise
- BTIG’s Krinsky warns 2000-like signals are mounting
- HSBC remains max bullish on stocks, tells investors to lean into tech
- Analyst explains why the midterm outcome is a “fundamental non-event”
- Oil settles up around 4% as Iran's president vows to never surrender
- Wall Street ends down as oil prices, Treasury yields rise
- Anthropic's Claude AI identifies novel enzyme system in DNA search
- AppLovin (APP) on watch amid 3% drop premarket as boutique comments circulate
- Plug Power COO resigns to join another company
- Xtend AI Robotics wins Phase III of USSOCOM lethal drone program
Ligand Pharma (LGND) Tops Q4 EPS by 43c, Offers Guidance
February 17, 2022 4:03 PM ESTLigand Pharma (NASDAQ: LGND) reported Q4 EPS of $1.80, $0.43 better than the analyst estimate of $1.37. Revenue for the quarter came in at $72.5 million versus the consensus estimate of $65.32 million.
GUIDANCE:
Ligand Pharma sees FY2022 revenue of $147-172 million, versus the consensus of... More
